Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 14.2% in December

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the recipient of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,030,000 shares, a decline of 14.2% from the December 15th total of 1,200,000 shares. Based on an average daily trading volume, of 131,000 shares, the short-interest ratio is presently 7.9 days. Approximately 1.8% of the shares of the company are short sold.

Institutional Trading of Nautilus Biotechnology

Hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in Nautilus Biotechnology in the 3rd quarter worth about $50,000. The Manufacturers Life Insurance Company bought a new position in Nautilus Biotechnology during the third quarter worth about $67,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Nautilus Biotechnology by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock worth $69,000 after purchasing an additional 9,404 shares in the last quarter. MetLife Investment Management LLC bought a new stake in shares of Nautilus Biotechnology in the third quarter valued at approximately $87,000. Finally, Barclays PLC raised its position in shares of Nautilus Biotechnology by 79.6% in the third quarter. Barclays PLC now owns 106,174 shares of the company’s stock valued at $303,000 after purchasing an additional 47,059 shares during the period. 50.71% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group downgraded Nautilus Biotechnology from a “neutral” rating to a “sell” rating and decreased their price target for the company from $2.25 to $1.75 in a research report on Thursday, December 5th.

Nautilus Biotechnology Stock Down 2.1 %

NASDAQ NAUT traded down $0.04 during trading hours on Thursday, reaching $1.90. 68,207 shares of the company were exchanged, compared to its average volume of 139,801. The stock has a market capitalization of $238.56 million, a P/E ratio of -3.39 and a beta of 1.20. Nautilus Biotechnology has a 1 year low of $1.61 and a 1 year high of $3.12. The business’s 50 day simple moving average is $2.05 and its 200-day simple moving average is $2.43.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.04. During the same quarter in the previous year, the business posted ($0.13) EPS. As a group, sell-side analysts anticipate that Nautilus Biotechnology will post -0.57 earnings per share for the current year.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.